CVS Health Plans to Split Off Its Pharmacy Chain: What Unwinding Health Care’s Biggest Vertical Bet Means for Dealmakers

CVS Health plans to separate its retail pharmacy business from its insurance, pharmacy benefit and care delivery operations, creating two independent, publicly traded companies by the first half of 2028. The company disclosed the plan on November 4 alongside third-quarter results, in what Bloomberg News described as one of the biggest health care breakups ever. The move would effectively unwind the vertical integration strategy CVS built around its $78 billion acquisition of Aetna in 2018, and it lands at a moment when lawmakers in both parties have been questioning the size and structure of the largest health conglomerates.

For executives tracking health care M&A, technology platforms and the economics of integrated care, the CVS decision is more than a single corporate event. It is a signal about how boards are now weighing the costs and benefits of owning every link in the chain, from the insurance card to the pharmacy counter.

What CVS announced

According to the company announcement summarized by The American Journal of Managed Care, the split follows a comprehensive strategic review by the CVS board. Shareholders would own shares in both companies after the separation, which is intended to be tax-free for federal income tax purposes. Completion still requires customary conditions, including final board approval and an effective Form 10 registration with the Securities and Exchange Commission.

The two companies would look like this:

• A health care solutions company, carrying the CVS Health name on an interim basis, that keeps insurer Aetna, pharmacy benefit manager CVS Caremark, CVS Specialty, primary care provider Oak Street Health and in-home health business Signify Health. Chairman and CEO David Joyner would stay in both roles.
• CVS Pharmacy, a standalone company holding about 9,000 retail pharmacies, mail pharmacies, MinuteClinic (including virtual care) and Health100, a technology services business the company describes as AI-native. Prem Shah, currently group president, would become CEO. Additional leadership and board members are to be named later.

CVS said customers should see no interruption in service. The pharmacy company plans to expand services delivered by its nearly 30,000 pharmacists and pursue more partnerships with payers, PBMs and manufacturers. Joyner framed the pharmacy business as the “front door” to health care, the consumer touchpoint people visit most often.

The numbers behind the decision

The company paired the announcement with stronger-than-expected results. Third-quarter revenue reached $108.40 billion, compared with $102.87 billion a year earlier. Bloomberg reported that CVS raised its 2026 profit outlook to at least $8.20 per share, from a prior range of $7.90 to $8.10, and that executives guided to 2027 adjusted earnings of at least $8.65 per share.

Joyner has been CEO since October 2024. His turnaround has included cost cuts, store closures, leadership changes and tighter cost controls in Medicare Advantage. Shares had risen about 70% under his tenure, bringing the company’s market value to roughly $117 billion. Even so, Bloomberg reported that CVS shares fell as much as 14% in New York trading on the day of the announcement, wiping out most of the year’s gains.

The retail segment is large by any measure. Bloomberg noted that pharmacy and consumer wellness revenue topped $139 billion last year, about a third of total company revenue, with significant overlap among segments. CVS has closed hundreds of stores in recent years while competitors Walgreens and Rite Aid have struggled.

Why the market was surprised

Reports of a possible breakup emerged the afternoon before the announcement and caught some analysts off guard. Leerink Partners analyst Michael Cherny called the news a complete shock, Bloomberg reported, because the pharmacy and wellness business had been performing well. In a note cited by AJMC, Cherny said retail pharmacy has been gaining market share and gross margins have been stabilizing under CostVantage, the reimbursement model CVS introduced last year that ties drug-dispensing payments more closely to costs. He also suggested the separation could help the company sidestep state legislative scrutiny of vertical integration, and wrote that a standalone pharmacy with scale may now look stronger than before.

Others were more cautious. RBC analyst Ben Hendrix said the standalone pharmacy’s long-term position will draw scrutiny given an already challenged retail environment. Bloomberg Intelligence’s Jean-Yves Coupin noted that spinning off a lower-growth, lower-margin retail unit creates uncertainty about capital structure, though lower leverage should help the new company maintain an investment-grade rating. CVS has not said how its debt will be divided; Joyner said both companies will have solid investment-grade balance sheets.

There is also a strategic reversal to reckon with. Bloomberg pointed out that the plan conflicts with the case CVS made at its investor day last year, when leadership argued that common ownership simplifies the consumer experience through shared technology. Executives now argue that two focused companies would be more nimble and simpler for customers. Joyner said the retail business has long operated somewhat independently of the enterprise, behind a firewall and negotiating at arm’s length with other units, and that it historically did not receive the same capital investment as other parts of the company.

The regulatory backdrop executives cannot ignore

The CVS decision did not happen in a vacuum. PBMs have faced sustained bipartisan criticism over opaque pricing, market power and conflicts of interest. Congress enacted PBM reforms in February that included changes to Medicare Part D compensation, and AJMC, citing Managed Healthcare Executive, noted that Arkansas and Tennessee have passed laws prohibiting PBMs from owning pharmacies. Bloomberg reported that lawmakers of both parties criticized the size of CVS and its rivals when their CEOs testified before Congress earlier this year, and that federal and state proposals to break up health conglomerates have been circulating.

One reason integration draws fire is accounting visibility. When one company owns the insurer, the PBM, the pharmacy and the clinic, internal costs such as dispensing drugs or delivering care can appear as revenue for another unit. Separating the pharmacy business makes those flows more transparent and could reduce exposure to laws targeting PBM ownership of pharmacies.

What this means for health care dealmakers and technology leaders

For boards, investors and operators across health care, the CVS move carries several lessons worth discussing in the next strategy session:

1. Vertical integration is no longer a default. The largest example of insurer, PBM and pharmacy integration in the country is choosing to separate. Boards pursuing roll-ups across the care chain should expect sharper questions about whether integration creates value or mainly creates regulatory and political risk.
2. Carve-outs create deal flow. Separations of this size tend to generate partnership, licensing and asset opportunities. A standalone CVS Pharmacy has said it will seek more partnerships with payers, PBMs and manufacturers, which could open doors for technology vendors, specialty pharmacy partners and services firms.
3. Technology and data rights become negotiating points. CVS placed Health100, its AI-native technology services business, with the pharmacy company. Any separation of this kind raises practical questions about shared platforms, data-sharing agreements, transition services and the ownership of intellectual property. Executives at companies doing business with either side should review contracts to understand which entity will hold their agreements after the split.
4. Capital allocation is part of the thesis. Joyner’s comment that retail has historically received less capital than other units is a reminder that conglomerate structures can starve otherwise healthy businesses. Acquirers should test whether a target’s growth has been limited by its parent’s priorities.
5. Regulatory design shapes structure. State laws barring PBM ownership of pharmacies and federal PBM reform are now influencing corporate structure directly. Deal teams should model how pending legislation could change the value of integrated assets.

Questions to ask your team this week

• Do any of our contracts, data agreements or technology integrations run through CVS Caremark, Aetna, CVS Specialty, MinuteClinic or CVS retail, and which entity will hold them after 2028?
• If we own or are evaluating integrated assets, how exposed are we to the same legislative pressures that shaped this decision?
• Are there partnership or acquisition opportunities that a standalone pharmacy company, or a more focused health care solutions company, might pursue?
• How would our own valuation change if the market began rewarding focus over scale?

What to watch next

The timeline is long. Key milestones to monitor include the SEC Form 10 filing and its disclosures about debt allocation, transition service agreements and intellectual property; the naming of the remaining CVS Pharmacy leadership team and board; how credit rating agencies treat both companies; and whether competitors with similar structures face renewed pressure from investors or lawmakers to follow. Investors will also watch whether the pharmacy business keeps gaining share under CostVantage and whether the health care solutions company can hold its Medicare Advantage cost gains.

The CVS breakup is a defining health care M&A story of the year, not because a deal closed but because a giant decided to undo one. For the executives we serve, it is a timely reminder that structure is strategy, and that the best transactions are the ones that still make sense when the political and regulatory winds shift. This article is general business information, not investment, legal or tax advice; consult qualified professionals before acting on any transaction.

Sources: The American Journal of Managed Care; Bloomberg News via the Jefferson City News-Tribune